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Abstract
The systemic inflammatory response following infectious or 
non-infectious insults is related to morbidity (including acute 
kidney injury) and mortality. Pregnancy is associated with im-
munotolerance and an increased glomerular filtration rate. 
EA-230, a linear tetrapeptide (Alanine-Glutamine-Glycine-
Valine), derived from the β-chain of the human chorionic go-
nadotropin hormone, has shown immunomodulatory and 
renoprotective properties in several pre-clinical animal mod-
els of systemic inflammation. Furthermore, an excellent safe-
ty profile of EA-230 was observed in phase 1 studies in hu-
mans, and the immunomodulatory effects of EA-230 were 
recently demonstrated in a phase IIa study during human ex-
perimental endotoxemia. A prospective double-blind place-
bo-controlled randomized trial in 180 patients undergoing 
elective CABG-surgery with or without valve surgery is cur-
rently conducted to investigate the immunomodulatory and 
renoprotective properties of EA-230. © 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Infectious (e.g., sepsis) and non-infectious conditions 
(e.g., trauma or major surgical interventions) activate the 
innate immune system, resulting in a systemic inflamma-
tory response. This activation of the immune system is 
essential for clearance of pathogens and initiation of tis-
sue repair. However, a too persistent or overwhelming 
inflammatory response can be detrimental, as it may lead 
to tissue damage and organ dysfunction with associated 
mortality rates up to 30% [1].
Development of acute kidney injury (AKI) is one of the 
first and most frequent manifestations of organ failure in 
systemic inflammation-related conditions and occurs in 
over a half of critically ill patients [2]. AKI has been as-
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sociated with impaired clinical outcome and mortality; 
even a minimal increase in serum creatinine has been 
shown to correlate with impaired survival in patients un-
dergoing elective cardiac surgery [2, 3]. 
It is increasingly recognized that inflammation plays a 
key role in the pathogenesis of AKI. This is for instance 
illustrated by associations between plasma levels of key 
inflammatory mediators, such as interleukin (IL)-6, and 
the development of AKI and mortality following cardiac 
surgery [4] and sepsis [5]. Despite the impact of systemic 
inflammation and the associated development of AKI, no 
immunomodulatory interventions have proven to be ef-
fective in regulating the systemic inflammatory response 
to prevent organ damage. Clearly, novel therapeutic strat-
egies are warranted. 
What Can We Learn from Pregnancy in the Search for 
New Immunomodulatory Therapies?
Pregnancy is an improbable symbiosis of 2 major 
histocompatibility complex-incompatible individuals. 
The adaptation of the maternal immune system during 
pregnancy has sparked research into new immuno-
modulatory strategies. This is based on the fact that 
pregnancy represents a unique immunologic situation 
in which the maternal immune system is adapted to tol-
erate the semi-allogeneic foetus, while maintaining the 
capacity to clear invading pathogens. Interestingly, the 
attenuated disease activity of various auto-immune dis-
eases like rheumatoid arthritis and multiple sclerosis 
during pregnancy represents another hallmark of this 
immune-tolerant anti-inflammatory phenotype, un-
derscored by the fact that these diseases often relapse 
following delivery [6]. These features are suggestive of 
specific modulation of the immune system in such a 
way that harmful immune processes to mother and foe-
tus are suppressed, while beneficial immune processes 
remain unaffected. If a pharmacological compound 
could mimic these effects, immune suppression with-
out the increased susceptibility for infections would be 
possible. 
β-Human Chorionic Gonadotropin-Derived 
Immunoactive Oligopeptides
In the last decades, several theories have been postu-
lated concerning the exact mechanisms behind the preg-
nancy-associated immune-tolerant phenotype. Of these, 
the hormonal milieu and, in particular, the release of 
human chorionic gonadotropin (hCG), is believed to 
play a pivotal role. hCG is present already at a very early 
stage, is produced throughout pregnancy and has been 
shown to exert immunomodulatory effects [7]. This has 
led to the discovery of immunologically active frag-
ments originating from the β-loop of hCG, which are 
abundantly present during pregnancy [8]. Recent stud-
ies in animal models of systemic inflammation showed 
that these oligopeptides exert immunomodulatory 
properties and limit organ failure and mortality [8–11]. 
Of particular interest is the linear tetrapeptide Alanine-
Glutamine-Glycine-Valine, later coined EA-230, which 
showed high efficacy in terms of beneficial effects [8, 10, 
12]. EA-230 prevented mortality in endotoxemic mice 
both when administered early (2 h) and late (24 h) after 
endotoxin administration [10]. Furthermore, a cocktail 
of 3 oligopeptides including EA-230 reduced the sever-
ity of sepsis induced by infusion of live E. coli in rhesus 
monkeys [10]. EA-230 also mitigated the release of in-
flammatory mediators, preserved renal function and 
improved survival in murine models of renal ischaemia-
reperfusion and kidney transplantation [12, 13]. Finally, 
EA-230 prevented the release of systemic inflammatory 
mediators, attenuated tissue neutrophil infiltration, and 
reduced organ damage in haemorrhagic shock-induced 
systemic inflammation in mice [9]. Because of these 
promising results, EA-230 was advanced into clinical 
development.
Clinical Studies with EA-230
A recent phase I safety study in healthy volunteers re-
vealed that intravenous administration of EA-230 is well 
tolerated and has an excellent safety profile [14]. A phase 
IIa study was subsequently conducted during experimen-
tal human endotoxemia, a human in vivo model of con-
trolled systemic inflammation elicited by the administra-
tion of a low dose of E. coli endotoxin. In this study, sub-
jects were treated with escalating doses of EA-230 (15, 45, 
90 mg/kg/h) or placebo for 2 h. Administration of the 
highest dose of EA-230 resulted in reduced levels of pro-
inflammatory mediators (IL-6 and IL-8, among others), 
significantly less flu-like symptoms and attenuated devel-
opment of fever compared to placebo-treated subjects 
[14].
The structure of EA-230 and a summary of its ef-
fects in previous pre(clinical) studies is provided in Fig-
ure 1.
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Future Directions
A clinical study is now warranted to investigate wheth-
er EA-230 also modulates the systemic inflammatory re-
sponse in patients, to explore whether this is beneficial in 
terms of organ (kidney) function, and to confirm the safe-
ty profile obtained in animals and healthy volunteers. 
Elective surgery patients represent an ideal patient group 
to investigate the putative beneficial effects of EA-230, as 
the compound can be administrated during the period 
that the inflammatory response and the insult to the kid-
neys occur. In addition, cardiac surgery patients repre-
sent a relatively homogeneous group, which displays a 
clinically relevant and reproducible inflammatory re-
sponse. Therefore, a double-blind, randomized, placebo-
controlled phase II trial is currently being conducted with 
EA-230 in patients undergoing elective cardiac surgery 
using cardiopulmonary bypass (www.clinicaltrials.gov; 
NCT03145220). One hundred and eighty patients will be 
randomized to either 90 mg/kg/h EA-230 or placebo. 
Study drug infusion will be initiated upon the first inci-
sion made by the surgeon and will continue as long as the 
patient is on extracorporeal circulation. Serial blood sam-
ples will be drawn to determine inflammatory mediators. 
In addition, renal function (glomerular filtration rate) 
will be determined on the day prior to surgery and on the 
day after surgery using iohexol methodology [15]. Sec-
ondary endpoints include safety and pharmacokinetics, 
circulating inflammatory markers (IL-6, tumour necrosis 
factor-α, IL-8, IL-10, IL-1 receptor antagonist, monocyte 
chemoattractant protein-1, IL12p70, macrophage in-
flammatory protein [MIP]-1α, MIP-1β), renal injury de-
termined by plasma levels and urinary excretion of tubu-
lar injury markers (including kidney injury marker-1, 
neutrophil gelatinase-associated lipocalin, fatty acid-
binding protein, tissue inhibitor metalloproteinase-2 and 
insulin-like growth factor binding protein-7, Proenkeph-
alin) and clinical sequela (including fluid balance, vaso-
pressor need, insulin-sensitivity and SOFA and SIRS 
scores). Patient enrolment and 90-day follow-up were re-
cently completed and database lock will be performed in 
May 2018.
Conclusion
Systemic inflammation is a complex and dynamic pro-
cess. An overwhelming or too persistent response can 
lead to tissue damage and organ failure, in which, par-
ticularly, the kidneys are affected. Treatments aiming to 
prevent AKI are warranted because kidney injury is cor-
related with mortality in critically ill patients. So far, ther-
apeutic strategies have failed to improve outcome, and 
current therapy only consists of supportive treatment. 
β-hCG-derived oligopeptides have been shown to exert 
immunomodulatory effects associated with the preserva-
tion of kidney function and reduction of mortality in var-
ious preclinical studies. Immunomodulatory effects of 
EA-230, which is one of the oligopeptides displaying high 
efficacy, were recently confirmed in an experimental hu-
man endotoxemia trial. Currently, a large double blind 
placebo-controlled randomized phase II clinical trial is 
underway to evaluate EA-230’s immunomodulatory and 
renoprotective effects in patients with systemic inflam-
mation following cardiac surgery.
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Pre-clinical studies:
↓ Pro-inflammatory cytokine production
↓ Tissue influx of neutrophils
↓ Less organ damage
↓ Kidney injury
↓ Mortality  
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Fig. 1. Structure of EA-230 and summary of its effects as reported in previous pre(clinical) studies.
Immunomodulatory and Protective 
Effects of the hCG Derivate EA-230
151Nephron 2018;140:148–151
DOI: 10.1159/000490772
References
 1 Vincent JL, Sakr Y, Sprung CL, Ranieri VM, 
Reinhart K, Gerlach H, et al: Sepsis in Euro-
pean intensive care units: results of the SOAP 
study. Crit Care Med 2006; 34: 344–353.
 2 Hoste EA, Bagshaw SM, Bellomo R, Cely CM, 
Colman R, Cruz DN, et al: Epidemiology of 
acute kidney injury in critically ill patients: the 
multinational AKI-EPI study. Intensive Care 
Med 2015; 41: 1411–1423.
 3 iotta M, Olsson D, Sartipy U, Holzmann MJ: 
Minimal changes in postoperative creatinine 
values and early and late mortality and car-
diovascular events after coronary artery by-
pass grafting. Am J Cardiol 2014; 113: 70–75.
 4 Zhang WR, Garg AX, Coca SG, Devereaux PJ, 
Eikelboom J, Kavsak P, et al: Plasma IL-6 and 
IL-10 concentrations predict AKI and long-
term mortality in adults after cardiac surgery. 
J Am Soc Nephrol 2015; 26: 3123–3132.
 5 Payen D, Lukaszewicz AC, Legrand M, Gayat 
E, Faivre V, Megarbane B, et al: A multicentre 
study of acute kidney injury in severe sepsis 
and septic shock: association with inflamma-
tory phenotype and HLA genotype. PLoS One 
2012; 7:e35838.
 6 Kaaja RJ, Greer IA: Manifestations of chronic 
disease during pregnancy. JAMA 2005; 294: 
2751–2757.
 7 Wan H, Versnel MA, Leijten LM, van Hel-
den-Meeuwsen CG, Fekkes D, Leenen PJ, et 
al: Chorionic gonadotropin induces dendritic 
cells to express a tolerogenic phenotype. J 
Leukoc Biol 2008; 83: 894–901.
 8 Khan NA, Benner R: Human chorionic go-
nadotropin: a model molecule for oligopep-
tide-based drug discovery. Endocr Metab 
Immune Disord Drug Targets 2011; 11: 32–
53.
 9 van den Berg HR, Khan NA, van der Zee M, 
Bonthuis F, IJzermans JN, Dik WA, et al: Syn-
thetic oligopeptides related to the [beta]-sub-
unit of human chorionic gonadotropin atten-
uate inflammation and liver damage after 
(trauma) hemorrhagic shock and resuscita-
tion. Shock 2009; 31: 285–291.
10 Khan NA, Vierboom MP, van Holten-Neelen 
C, Breedveld E, Zuiderwijk-Sick E, Khan A, et 
al: Mitigation of septic shock in mice and rhe-
sus monkeys by human chorionic gonadotro-
phin-related oligopeptides. Clin Exp Immu-
nol 2010; 160: 466–478.
11 van den Berg JW, Dik WA, van der Zee M, 
Bonthuis F, van Holten-Neelen C, Dingjan 
GM, et al: The β-human chorionic gonado-
tropin-related peptide LQGV reduces mor-
tality and inflammation in a murine polymi-
crobial sepsis model. Crit Care Med 2011; 39: 
126–134.
12 Khan NA, Susa D, van den Berg JW, Huis-
man M, Ameling MH, van den Engel S, et 
al: Amelioration of renal ischaemia-reper-
fusion injury by synthetic oligopeptides 
 related to human chorionic gonadotropin. 
Nephrol Dial Transplant 2009; 24: 2701–
2708.
13 Gueler F, Shushakova N, Mengel M, 
Hueper K, Chen R, Liu X, et al: A novel ther-
apy to  attenuate acute kidney injury and 
 ischemic  allograft damage after allogenic kid-
ney  transplantation in mice. PLoS One 2015; 
10:e0115709.
14 van Groenendael R, van Eijk L, Aarnoutse R, Lei-
jte GP, Koeneman B, Kox M, Pickkers P: Safety, 
Tolerability, and Immunomodulatory Effects of 
EA-230 in Humans. Abstract ESICM, 2016. 
https://icm-experimentalspringeropencom/
articles/101186/s40635-016-0098-x.
15 Delanaye P, Ebert N, Melsom T, Gaspari F, 
Mariat C, Cavalier E, et al: Iohexol plasma 
clearance for measuring glomerular filtration 
rate in clinical practice and research: a review. 
Part 1: How to measure glomerular filtration 
rate with iohexol? Clin Kidney J 2016; 9: 682–
699.
